Lucid Diagnostics Inc. (LUCD)
NASDAQ (CM) NASDAQ (CM) Primary 
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.16 per share a year ago.
Lucid Diagnostics Inc. (LUCD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Q4 2025 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.19 per share a year ago.
Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call Transcript
Lucid Diagnostics Inc. ( LUCD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Matthew Riley - Director of Investor Relations Lishan Aklog - Chairman & CEO Dennis McGrath - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG, LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Anthony Vendetti - Maxim Group LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2025 Business Update Conference Call. Please note, this event is being recorded.
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.
Lucid Diagnostics Inc. (LUCD) Q2 2025 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q2 2025 Earnings Call August 13, 2025 8:30 AM ET Company Participants Dennis M. McGrath - Chief Financial Officer Lishan Aklog - Chairman & CEO Matthew Riley - Director of Investor Relations Conference Call Participants Anthony V.
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Tops Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.2 per share a year ago.
Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2025 Business Update Conference Call May 14, 2025 8:30 AM ET Company Participants Matt Riley – Senior Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – Chief Financial Officer Conference Call Participants Mark Massaro – BTIG Kyle Mikson – Canaccord Genuity Mike Matson – Needham & Company Jeremy Pearlman – Maxim Group Ross Osborn – Cantor Fitzgerald Ed Woo – Ascendiant Capital Operator Good morning and welcome to the Lucid Diagnostics First Quarter 2025 Business Update Conference Call. Please note, this event is being recorded.
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.21 per share a year ago.
